Newer drugs for treating atrial fibrillation include oral anticoagulants such as dabigatran etexilate, rivaroxaban, apixaban. Drugs that slow the ventricular rate such as cediran and digoxin. Drugs that slow down the ventricular rate can act on the atrioventricular bundle to slow down the conduction between the atria and the ventricles, so that the ventricular rate of patients with atrial fibrillation can be controlled in an appropriate range. In addition to the above-mentioned digitalis drugs, there are also β-blockers, metoprolol, which are commonly used in the clinic. New oral anticoagulants are mainly used for anticoagulation treatment of non-valvular atrial fibrillation to prevent the formation of thrombus in the atria, which is characterized by better safety as it does not require routine coagulation index monitoring and is less likely to be affected by drugs or food. The treatment of atrial fibrillation emphasizes long-term comprehensive management, based on the treatment of the primary disease, active prevention of thromboembolism, reversal and maintenance of sinus rhythm and control of ventricular rate.